All News about Genmab A/S ADR
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_4.png?width=1200&height=800&fit=crop)
What 8 Analyst Ratings Have To Say About Genmab
July 15, 2024
Via Benzinga
![](https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp)
![](https://www.chartmill.com/images/uploads/Undervalued_500_264px_webp_74997b3ff2.webp)
![](https://mms.businesswire.com/media/20240627569754/en/2172406/5/Genmab_Logo_Color_RGB.jpg)
![](https://cdn.benzinga.com/files/images/story/2024/06/27/AbbVie-Office.png?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_0.png?width=1200&height=800&fit=crop)
10 Analysts Assess Genmab: What You Need To Know
June 20, 2024
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_2.jpeg?width=1200&height=800&fit=crop)
What 9 Analyst Ratings Have To Say About Genmab
May 20, 2024
Via Benzinga
![](https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp)
![](https://mms.businesswire.com/media/20240626204925/en/2171499/5/Genmab_Logo_Color_RGB.jpg)
![](https://investorplace.com/wp-content/uploads/2022/10/biotechnology1600.png)
![](https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp)
![](https://investorplace.com/wp-content/uploads/2024/01/arrow-graphic-growth-stocks-1600.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_1.jpeg?width=1200&height=800&fit=crop)
Decoding 9 Analyst Evaluations For Genmab
April 30, 2024
Via Benzinga
Via Chartmill
![](https://mms.businesswire.com/media/20240603640244/en/2146969/22/GenmabLogo.jpg)
![](https://mms.businesswire.com/media/20240602990089/en/2147628/5/Genmab_Logo_Color_RGB.jpg)
![](https://mms.businesswire.com/media/20240601902871/en/2147002/5/Genmab_Logo_Color_RGB.jpg)
![](https://cdn.benzinga.com/files/images/story/2024/05/24/xrdDAFjtxJSjsw2-j47730601021-t23052308.jpeg?width=1200&height=800&fit=crop)
![](https://mms.businesswire.com/media/20240523620002/en/2138830/22/GenmabLogo.jpg)
![](https://mms.businesswire.com/media/20240521989095/en/2137492/5/Genmab_Logo_Color_RGB.jpg)
![](https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600.png)
![](https://mms.businesswire.com/media/20240514430927/en/2129709/5/Genmab_Logo_Color_RGB.jpg)
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
![](https://mms.businesswire.com/media/20240422914519/en/2105097/22/GenmabLogo.jpg)
![](https://mms.businesswire.com/media/20240415775924/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
![](https://www.investors.com/wp-content/uploads/2024/04/TECH1_radiopharma_042624_shutter.jpg)
![](https://cdn.benzinga.com/files/profoundbio-0408-01.jpeg?width=1200&height=800&fit=crop)
![](https://www.investors.com/wp-content/uploads/2024/04/Stock-genmab-01-shutt.jpg)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.